search icon
      blog search icon

      BDRX Stock Price History and Quote Analysis: Insights for Investors

      Biodexa Pharmaceuticals Plc

      (NASDAQ:BDRX)

      $3.75

      0.13 (3.59%)

      At Close: 4:00 PM

      BDRX Stock Price Graph

      • 1D
      • 5D
      • 1M
      • 3M
      • 6M
      • 1Y
      • YTD
      • All

      BDRX Stock Price Today

      Biodexa Pharmaceuticals Plc (BDRX) stock rallied over 3.59% intraday to trade at $3.75 a share on NASDAQ. The stock opened with a loss of -93.96% at $0.22 and touched an intraday high of $0.22, rising 3.59% against the last close of $3.62. The Biodexa Pharmaceuticals Plc in stock market went to a low of $0.20 during the session.

      BDRX Stock Snapshot

      $3.62

      Prev. Close

      900 Thousands

      Market Cap

      $0.20

      Day Low

      $0.22

      Open

      N/A

      Number of Shares

      $0.22

      Day High

      N/A

      P/E ratio

      -453.45

      EPS (TTM)

      7.52

      Cash Flow per Share

      N/A

      Free Float in %

      7.62

      Book Value

      240942.00

      Volume

      BDRX Stock Price History Chart

      DateOpenHighLowCloseVolume

      Contact Details

      1 Caspian Point
      Caspian Way
      Cardiff CF10 4DQ
      United Kingdom

      Website:https://www.biodexapharma.com

      Contact #:44 29 2048 0180

      Company Information

      Employees27.00

      Beta1.94

      Sales or Revenue$529 Thousands

      5Y Sales Change62.91%

      Fiscal Year EndsDec. 2022

      SectorHealthcare

      IndustryBiotechnology

      About Company

      Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

      Peers

      Frequently Asked Questions

      icon

      What is the current Biodexa Pharmaceuticals Plc (BDRX) stock price?

      Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) stock price is $3.75 in the last trading session. During the trading session, BDRX stock reached the peak price of $0.22 while $0.20 was the lowest point it dropped to. The percentage change in BDRX stock occurred in the recent session was 3.59% while the dollar amount for the price change in BDRX stock was $0.13.

      icon

      BDRX's industry and sector of operation?

      The NASDAQ listed BDRX is part of Biotechnology industry that operates in the broader Healthcare sector. Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection.

      icon

      Who are the executives of BDRX?

      Mr. David Benharris
      Pres of Midatech Pharma US Inc
      Mr. Vincent Holmes
      VP & Head of Clinical Operations
      Mr. Stephen A. Stamp
      CEO, CFO, Company Sec. & Director
      Dr. Dmitry Zamoryakhin M.D.
      Chief Scientific Officer

      icon

      How BDRX did perform over past 52-week?

      BDRX's closing price is 0.08% higher than its 52-week low of $0.19 where as its distance from 52-week high of $20.8 is -0.99%.

      icon

      How many employees does BDRX have?

      Number of BDRX employees currently stands at 27.00. BDRX operates from 1 Caspian Point<br/>Caspian Way<br/>Cardiff CF10 4DQ<br/>United Kingdom.

      icon

      Link for BDRX official website?

      Official Website of BDRX is: https://www.biodexapharma.com

      icon

      How do I contact BDRX?

      BDRX could be contacted at phone #44 29 2048 0180 and can also be accessed through its website. BDRX operates from 1 Caspian Point<br/>Caspian Way<br/>Cardiff CF10 4DQ<br/>United Kingdom.

      icon

      How many shares of BDRX are traded daily?

      BDRX stock volume for the day was 240942.00 shares. The average number of BDRX shares traded daily for last 3 months was 878.72 Thousands.

      icon

      What is the market cap of BDRX currently?

      The market value of BDRX currently stands at $900 Thousands with its latest stock price at $3.75 and N/A of its shares outstanding.